Boston University

The global non-profit Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), which provides funding and other support for early-stage development of treatments, diagnostics an

It took four weeks, but the second quarter of 2022 finally has its first two biopharmaceutical initial public offerings in the US, launched by HilleVax, Inc. and Belite Bio late on 28 April. The o

Below is Scrip’s monthly roundup, including information from Strategic Transactions , of recent technology transfer agreements between companies and academic or other research institutions. Amgen, M

For the legions of highly-paid professionals that run today’s biopharmaceutical enterprise, the wild card question of 2017 cuts disturbingly close: are you and your company prepared for a world that n